

Welcome to STN International! Enter x:x

LOGINID:sssptaul87mxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/CAPLUS
NEWS 5 FEB 05 German (DE) application and patent publication number format
changes
NEWS 6 MAR 03 MEDLINE and LMEADLINE reloaded
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03 FRANCEPAT now available on STN
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29 WPIFV now available on STN
NEWS 11 MAR 29 No connect hour charges in WPIFV until May 1, 2004
NEWS 12 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 13 APR 26 PROMT: New display field available
NEWS 14 APR 26 FIPAT/IFIUDB/IFICDB: New super search and display field
available
NEWS 15 APR 26 LITALERT now available on STN

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:48:03 ON 27 APR 2004

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 10:48:18 ON 27 APR 2004

FILE LAST UPDATED: 24 APR 2004 (20040424/UP). FILE COVERS 1951 TO DATE.

On February 29, 2004, the 2004 MeSH terms were loaded. See HELP RLOAD for details. OLDMEDLINE now back to 1951.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2004 vocabulary. See <http://www.nlm.nih.gov/mesh/> and http://www.nlm.nih.gov/pubs/techbull/nd03/nd03_mesh.html for a description of changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s influenza neuraminidase

38952 INFLUENZA

13492 NEURAMINIDASE

L1 91 INFLUENZA NEURAMINIDASE
(INFLUENZA(W) NEURAMINIDASE)

=> s immun? and l1

1595564 IMMUN?

L2 31 IMMUN? AND L1

=> d ti 1-10

L2 ANSWER 1 OF 31 MEDLINE on STN

TI Structure of an **influenza neuraminidase**-diabody complex by electron cryomicroscopy and image analysis.

L2 ANSWER 2 OF 31 MEDLINE on STN

TI Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada.

L2 ANSWER 3 OF 31 MEDLINE on STN

TI Influenza: vaccination and treatment.

L2 ANSWER 4 OF 31 MEDLINE on STN

TI Design and application of diabodies, triabodies and tetrabodies for cancer targeting.

L2 ANSWER 5 OF 31 MEDLINE on STN

TI Recent advances in the study, prevention, and treatment of infectious diseases.

L2 ANSWER 6 OF 31 MEDLINE on STN

TI The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.

L2 ANSWER 7 OF 31 MEDLINE on STN

TI Evaluation of recombinant A/Victoria/3/75 (H3N2) **influenza neuraminidase** mutants as potential broad-spectrum subunit vaccines against influenza A.

L2 ANSWER 8 OF 31 MEDLINE on STN

TI New approaches to influenza chemotherapy. Neuraminidase inhibitors.

L2 ANSWER 9 OF 31 MEDLINE on STN

TI Protection of mice against a lethal influenza challenge by **immunization** with yeast-derived recombinant **influenza neuraminidase**.

L2 ANSWER 10 OF 31 MEDLINE on STN

TI Solution properties of Escherichia coli-expressed VH domain of anti-neuraminidase antibody NC41.

=> d 7

L2 ANSWER 7 OF 31 MEDLINE on STN
AN 1999073319 MEDLINE
DN PubMed ID: 9856088
TI Evaluation of recombinant A/Victoria/3/75 (H3N2) **influenza neuraminidase** mutants as potential broad-spectrum subunit vaccines against influenza A.
AU Martinet W; Deroo T; Saelens X; Beirnaert E; Vanlandschoot P; Contreras R; Fiers W; Min Jou W
CS Department of Molecular Biology, Flanders Interuniversity Institute for biotechnology, Ghent, Belgium.
SO Archives of virology, (1998) 143 (10) 2011-9.
Journal code: 7506870. ISSN: 0304-8608.
CY Austria
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199901
ED Entered STN: 19990115
Last Updated on STN: 19990115
Entered Medline: 19990104

=> d 9

L2 ANSWER 9 OF 31 MEDLINE on STN
AN 97390105 MEDLINE
DN PubMed ID: 9249044
TI Protection of mice against a lethal influenza challenge by **immunization** with yeast-derived recombinant **influenza neuraminidase**.
AU Martinet W; Saelens X; Deroo T; Neirynck S; Contreras R; Min Jou W; Fiers W
CS Laboratory of Molecular Biology, Flanders Interuniversity Institute for Biotechnology and University of Ghent, Belgium.
SO European journal of biochemistry / FEBS, (1997 Jul 1) 247 (1) 332-8.
Journal code: 0107600. ISSN: 0014-2956.
CY GERMANY: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199708
ED Entered STN: 19970902
Last Updated on STN: 19970902
Entered Medline: 19970821

=> d ti 11-20

L2 ANSWER 11 OF 31 MEDLINE on STN
TI Red cells bound to influenza virus N9 neuraminidase are not released by the N9 neuraminidase activity.

L2 ANSWER 12 OF 31 MEDLINE on STN
TI Db-binding peptides from influenza virus: effect of non-anchor residues on stability and **immunodominance**.

L2 ANSWER 13 OF 31 MEDLINE on STN
TI Affinity ranking of **influenza neuraminidase** mutants with monoclonal antibodies using an optical biosensor. Comparison with ELISA and slot blot assays.

L2 ANSWER 14 OF 31 MEDLINE on STN

TI Expression of **influenza neuraminidase** in baculovirus-infected cells.

L2 ANSWER 15 OF 31 MEDLINE on STN

TI Spot-scan imaging of microcrystals of an **influenza neuraminidase**-antibody fragment complex.

L2 ANSWER 16 OF 31 MEDLINE on STN

TI Measurement of anti-**influenza neuraminidase** antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates.

L2 ANSWER 17 OF 31 MEDLINE on STN

TI Characterisation of an avian influenza virus nucleoprotein expressed in *E. coli* and in insect cells.

L2 ANSWER 18 OF 31 MEDLINE on STN

TI Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections.

L2 ANSWER 19 OF 31 MEDLINE on STN

TI Site-directed mutation of the active site of **influenza neuraminidase** and implications for the catalytic mechanism.

L2 ANSWER 20 OF 31 MEDLINE on STN

TI Electron and X-ray diffraction studies of **influenza neuraminidase** complexed with monoclonal antibodies.

=> d 18

L2 ANSWER 18 OF 31 MEDLINE on STN

AN 90383440 MEDLINE

DN PubMed ID: 2401790

TI Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections.

AU Johansson B E; Kilbourne E D

CS Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029.

NC AI-10934 (NIAID)

SO Journal of infectious diseases, (1990 Oct) 162 (4) 800-9.
Journal code: 0413675. ISSN: 0022-1899.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199010

ED Entered STN: 19901122
Last Updated on STN: 19970203
Entered Medline: 19901019

=> d ab 18

L2 ANSWER 18 OF 31 MEDLINE on STN

AB A comparison of inactivated whole influenza virus vaccine and purified **influenza neuraminidase** (NA) in BALB/c mice repeatedly challenged by homologous or heterologous H3N2 variant infections demonstrated an initial superiority of whole virus vaccine but the ultimate superiority of NA vaccine in **immunization** after one or two boosting infections. Parenteral administration of either vaccine followed by infection was much more effective than infection alone in the

induction of either homologous or heterologous **immunity**. On the basis of this model simulation of human experience and other earlier studies, it seems that purified NA vaccine may offer an important new strategy as an initial step in **immunization** against influenza in humans.